Rolofylline

Rolofylline is a diuretic that was under development for the treatment of acute heart failure and associated renal dysfunction. It is a selective adenosine A1 receptor antagonist. Rolofylline was being developed by NovaCardia until 2007, when the company was acquired by Merck & Co.. In 2010, clinical trials were discontinued after it was found the drug did not significantly improve symptoms compared to a placebo.

History[edit | edit source]

Rolofylline was initially developed by NovaCardia, a pharmaceutical company specializing in cardiovascular diseases. In 2007, NovaCardia was acquired by Merck & Co., a multinational pharmaceutical company. The acquisition was part of Merck's strategy to strengthen its portfolio of cardiovascular drugs.

Mechanism of Action[edit | edit source]

Rolofylline is a selective adenosine A1 receptor antagonist. Adenosine A1 receptors are found in the heart and kidneys, among other places. By blocking these receptors, rolofylline is thought to increase urine production and decrease fluid buildup in the body, which can help alleviate symptoms of acute heart failure.

Clinical Trials[edit | edit source]

In 2010, Merck announced that it had discontinued clinical trials of rolofylline. The decision was based on the results of a Phase III clinical trial, which found that rolofylline did not significantly improve symptoms or clinical outcomes compared to a placebo in patients with acute heart failure and renal dysfunction.

See Also[edit | edit source]

Rolofylline Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.